New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 Editorial team, Elaine Ruth Fletcher & David Branigan WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> EU Calls For Results Of All EU-based Clinical Trials To Be Added To Public Database 04/07/2019 David Branigan The European Commission and European Union medicines regulatory agencies sent an open letter to all sponsors of EU-based clinical trials to remind them of their obligation to publish the results of the trials – both positive and negative – in a public database. The open letter by the European Commission (EC), the European Medicines Agency […] Continue reading -> GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> Gavi’s New 5-Year Strategy Prioritises Equity In Immunisation, Sustainable Financing 28/06/2019 David Branigan Gavi, the Vaccine Alliance, just finalised its new strategic plan for 2021-2025, which aims to reach communities missed by previous immunisation efforts, including those most marginalised by poverty, geography and conflict. It also prioritises sustainability of vaccine programmes through co-financing arrangements with countries to build domestic investment in health and reduce reliance on Gavi funding. […] Continue reading -> Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries 24/06/2019 Editorial team [By Reuters] NEW YORK (Reuters) – Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it[s] Medicare program on lower prices in other countries would face legal challenges if adopted. U.S. President Donald Trump said last year that one […] Continue reading -> Public Health-Driven R&D Focus Of Draft HRC Resolution On Access To Medicines & Vaccines 24/06/2019 David Branigan A United Nations Human Rights Council (HRC) draft resolution on access to medicines and vaccines calls for making public health needs more central to the research and development (R&D) of new health products, and for the new products to be priced to ensure access. Image Credits: United Nations. Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> New Resource Gateway Launched On Innovation & Access To Medicines 14/06/2019 Elaine Ruth Fletcher A new Knowledge Portal that aims to ease policymakers’ access to reliable information about themes in medicines access, pricing and pharma innovation was launched today by the Global Health Centre of Geneva’s Graduate Institute of International and Development Studies. The Portal currently covers some 17 topics grouped under three broad themes – Pricing, Intellectual Property […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
“Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> EU Calls For Results Of All EU-based Clinical Trials To Be Added To Public Database 04/07/2019 David Branigan The European Commission and European Union medicines regulatory agencies sent an open letter to all sponsors of EU-based clinical trials to remind them of their obligation to publish the results of the trials – both positive and negative – in a public database. The open letter by the European Commission (EC), the European Medicines Agency […] Continue reading -> GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> Gavi’s New 5-Year Strategy Prioritises Equity In Immunisation, Sustainable Financing 28/06/2019 David Branigan Gavi, the Vaccine Alliance, just finalised its new strategic plan for 2021-2025, which aims to reach communities missed by previous immunisation efforts, including those most marginalised by poverty, geography and conflict. It also prioritises sustainability of vaccine programmes through co-financing arrangements with countries to build domestic investment in health and reduce reliance on Gavi funding. […] Continue reading -> Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries 24/06/2019 Editorial team [By Reuters] NEW YORK (Reuters) – Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it[s] Medicare program on lower prices in other countries would face legal challenges if adopted. U.S. President Donald Trump said last year that one […] Continue reading -> Public Health-Driven R&D Focus Of Draft HRC Resolution On Access To Medicines & Vaccines 24/06/2019 David Branigan A United Nations Human Rights Council (HRC) draft resolution on access to medicines and vaccines calls for making public health needs more central to the research and development (R&D) of new health products, and for the new products to be priced to ensure access. Image Credits: United Nations. Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> New Resource Gateway Launched On Innovation & Access To Medicines 14/06/2019 Elaine Ruth Fletcher A new Knowledge Portal that aims to ease policymakers’ access to reliable information about themes in medicines access, pricing and pharma innovation was launched today by the Global Health Centre of Geneva’s Graduate Institute of International and Development Studies. The Portal currently covers some 17 topics grouped under three broad themes – Pricing, Intellectual Property […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
EU Calls For Results Of All EU-based Clinical Trials To Be Added To Public Database 04/07/2019 David Branigan The European Commission and European Union medicines regulatory agencies sent an open letter to all sponsors of EU-based clinical trials to remind them of their obligation to publish the results of the trials – both positive and negative – in a public database. The open letter by the European Commission (EC), the European Medicines Agency […] Continue reading -> GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> Gavi’s New 5-Year Strategy Prioritises Equity In Immunisation, Sustainable Financing 28/06/2019 David Branigan Gavi, the Vaccine Alliance, just finalised its new strategic plan for 2021-2025, which aims to reach communities missed by previous immunisation efforts, including those most marginalised by poverty, geography and conflict. It also prioritises sustainability of vaccine programmes through co-financing arrangements with countries to build domestic investment in health and reduce reliance on Gavi funding. […] Continue reading -> Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries 24/06/2019 Editorial team [By Reuters] NEW YORK (Reuters) – Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it[s] Medicare program on lower prices in other countries would face legal challenges if adopted. U.S. President Donald Trump said last year that one […] Continue reading -> Public Health-Driven R&D Focus Of Draft HRC Resolution On Access To Medicines & Vaccines 24/06/2019 David Branigan A United Nations Human Rights Council (HRC) draft resolution on access to medicines and vaccines calls for making public health needs more central to the research and development (R&D) of new health products, and for the new products to be priced to ensure access. Image Credits: United Nations. Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> New Resource Gateway Launched On Innovation & Access To Medicines 14/06/2019 Elaine Ruth Fletcher A new Knowledge Portal that aims to ease policymakers’ access to reliable information about themes in medicines access, pricing and pharma innovation was launched today by the Global Health Centre of Geneva’s Graduate Institute of International and Development Studies. The Portal currently covers some 17 topics grouped under three broad themes – Pricing, Intellectual Property […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> Gavi’s New 5-Year Strategy Prioritises Equity In Immunisation, Sustainable Financing 28/06/2019 David Branigan Gavi, the Vaccine Alliance, just finalised its new strategic plan for 2021-2025, which aims to reach communities missed by previous immunisation efforts, including those most marginalised by poverty, geography and conflict. It also prioritises sustainability of vaccine programmes through co-financing arrangements with countries to build domestic investment in health and reduce reliance on Gavi funding. […] Continue reading -> Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries 24/06/2019 Editorial team [By Reuters] NEW YORK (Reuters) – Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it[s] Medicare program on lower prices in other countries would face legal challenges if adopted. U.S. President Donald Trump said last year that one […] Continue reading -> Public Health-Driven R&D Focus Of Draft HRC Resolution On Access To Medicines & Vaccines 24/06/2019 David Branigan A United Nations Human Rights Council (HRC) draft resolution on access to medicines and vaccines calls for making public health needs more central to the research and development (R&D) of new health products, and for the new products to be priced to ensure access. Image Credits: United Nations. Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> New Resource Gateway Launched On Innovation & Access To Medicines 14/06/2019 Elaine Ruth Fletcher A new Knowledge Portal that aims to ease policymakers’ access to reliable information about themes in medicines access, pricing and pharma innovation was launched today by the Global Health Centre of Geneva’s Graduate Institute of International and Development Studies. The Portal currently covers some 17 topics grouped under three broad themes – Pricing, Intellectual Property […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Gavi’s New 5-Year Strategy Prioritises Equity In Immunisation, Sustainable Financing 28/06/2019 David Branigan Gavi, the Vaccine Alliance, just finalised its new strategic plan for 2021-2025, which aims to reach communities missed by previous immunisation efforts, including those most marginalised by poverty, geography and conflict. It also prioritises sustainability of vaccine programmes through co-financing arrangements with countries to build domestic investment in health and reduce reliance on Gavi funding. […] Continue reading -> Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries 24/06/2019 Editorial team [By Reuters] NEW YORK (Reuters) – Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it[s] Medicare program on lower prices in other countries would face legal challenges if adopted. U.S. President Donald Trump said last year that one […] Continue reading -> Public Health-Driven R&D Focus Of Draft HRC Resolution On Access To Medicines & Vaccines 24/06/2019 David Branigan A United Nations Human Rights Council (HRC) draft resolution on access to medicines and vaccines calls for making public health needs more central to the research and development (R&D) of new health products, and for the new products to be priced to ensure access. Image Credits: United Nations. Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> New Resource Gateway Launched On Innovation & Access To Medicines 14/06/2019 Elaine Ruth Fletcher A new Knowledge Portal that aims to ease policymakers’ access to reliable information about themes in medicines access, pricing and pharma innovation was launched today by the Global Health Centre of Geneva’s Graduate Institute of International and Development Studies. The Portal currently covers some 17 topics grouped under three broad themes – Pricing, Intellectual Property […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries 24/06/2019 Editorial team [By Reuters] NEW YORK (Reuters) – Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it[s] Medicare program on lower prices in other countries would face legal challenges if adopted. U.S. President Donald Trump said last year that one […] Continue reading -> Public Health-Driven R&D Focus Of Draft HRC Resolution On Access To Medicines & Vaccines 24/06/2019 David Branigan A United Nations Human Rights Council (HRC) draft resolution on access to medicines and vaccines calls for making public health needs more central to the research and development (R&D) of new health products, and for the new products to be priced to ensure access. Image Credits: United Nations. Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> New Resource Gateway Launched On Innovation & Access To Medicines 14/06/2019 Elaine Ruth Fletcher A new Knowledge Portal that aims to ease policymakers’ access to reliable information about themes in medicines access, pricing and pharma innovation was launched today by the Global Health Centre of Geneva’s Graduate Institute of International and Development Studies. The Portal currently covers some 17 topics grouped under three broad themes – Pricing, Intellectual Property […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Public Health-Driven R&D Focus Of Draft HRC Resolution On Access To Medicines & Vaccines 24/06/2019 David Branigan A United Nations Human Rights Council (HRC) draft resolution on access to medicines and vaccines calls for making public health needs more central to the research and development (R&D) of new health products, and for the new products to be priced to ensure access. Image Credits: United Nations. Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> New Resource Gateway Launched On Innovation & Access To Medicines 14/06/2019 Elaine Ruth Fletcher A new Knowledge Portal that aims to ease policymakers’ access to reliable information about themes in medicines access, pricing and pharma innovation was launched today by the Global Health Centre of Geneva’s Graduate Institute of International and Development Studies. The Portal currently covers some 17 topics grouped under three broad themes – Pricing, Intellectual Property […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> New Resource Gateway Launched On Innovation & Access To Medicines 14/06/2019 Elaine Ruth Fletcher A new Knowledge Portal that aims to ease policymakers’ access to reliable information about themes in medicines access, pricing and pharma innovation was launched today by the Global Health Centre of Geneva’s Graduate Institute of International and Development Studies. The Portal currently covers some 17 topics grouped under three broad themes – Pricing, Intellectual Property […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Knowledge Portal On Innovation And Access To Medicines 14/06/2019 Editorial team Click here or on the image below to be redirected to the Knowledge Portal. Continue reading -> New Resource Gateway Launched On Innovation & Access To Medicines 14/06/2019 Elaine Ruth Fletcher A new Knowledge Portal that aims to ease policymakers’ access to reliable information about themes in medicines access, pricing and pharma innovation was launched today by the Global Health Centre of Geneva’s Graduate Institute of International and Development Studies. The Portal currently covers some 17 topics grouped under three broad themes – Pricing, Intellectual Property […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New Resource Gateway Launched On Innovation & Access To Medicines 14/06/2019 Elaine Ruth Fletcher A new Knowledge Portal that aims to ease policymakers’ access to reliable information about themes in medicines access, pricing and pharma innovation was launched today by the Global Health Centre of Geneva’s Graduate Institute of International and Development Studies. The Portal currently covers some 17 topics grouped under three broad themes – Pricing, Intellectual Property […] Continue reading -> Posts navigation Older postsNewer posts